Cryptosporidium parvum (C. parvum)

Cryptosporidium parvum is a major zoonotic protozoan parasite within the phylum Apicomplexa that serves as a primary causative agent of cryptosporidiosis, a severe diarrheal disease. The organism primarily infects the microvilli of the intestinal epithelium, leading to self-limiting watery diarrhea in healthy individuals but potentially fatal, chronic infection in immunocompromised patients and malnourished children. C. parvum is characterized by a highly streamlined genome and the absence of a functional apicoplast or mitochondrial oxidative phosphorylation, relying instead on anaerobic glycolysis and unique metabolic enzymes like pyruvate:ferredoxin oxidoreductase (PFOR). From a pharmacological perspective, while nitazoxanide is the only FDA-approved drug for treating cryptosporidiosis, its efficacy is insufficient in high-risk populations. Modern drug discovery treats the entire organism as a target by identifying essential parasite-specific proteins, such as Calcium-Dependent Protein Kinase 1 (CDPK1), Inosine-5'-monophosphate dehydrogenase (IMPDH), and Phosphatidylinositol 4-kinase (PI4K). These targets are exploited to develop selective inhibitors that disrupt the parasite's complex life cycle, which includes both asexual (merogony) and sexual (gametogony) phases within a single host.

Other names

Cryptosporidium parvum (parasite organism)C. parvum

Interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction; inhibition of protein synthesis (30S ribosomal subunit); inhibition of phosphatidylinositol 4-kinase (PI4K); inhibition of calcium-dependent protein kinases (CDPKs).